Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958565 | 1.00 | KMO (0.61) | KMOKMT2AOXER1NPY5RHTR7 | |
| SCHEMBL29174329 | 0.94 | KMO (0.63) | KMOKMT2AOXER1NPY5RHTR7 | |
| SCHEMBL2006946 | 0.87 | HTR2A (0.55) | KMOKMT2AOXER1NPY5RLMNA | |
| SCHEMBL1576364 | 0.85 | KMO (0.72) | KMOKMT2AOXER1NPY5RHTR7 | |
| SCHEMBL29957878 | 0.85 | KMO (0.72) | KMOKMT2AOXER1NPY5RHTR7 | |
| SCHEMBL3353214 | 0.82 | LMNA (0.44) | KMOKMT2ALMNAHTR2AHTR2C | |
| SCHEMBL10203771 | 0.81 | KMO (0.58) | KMOKMT2AOXER1NPY5RHTR7 | |
| SCHEMBL31177216 | 0.81 | HTR2C (0.55) | KMOKMT2ANPY5RHTR7LMNA | |
| SCHEMBL10165545 | 0.80 | KMO (0.57) | KMOKMT2AOXER1NPY5RHTR7 | |
| SCHEMBL24414633 | 0.79 | LMNA (0.42) | KMOKMT2ALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | claimed |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| CN-100364973-C | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2008-01-30 | — | — | CN | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KMO 204/4885KMT2A 1570/4885OXER1 2492/4885 |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | KMO 313/4885KMT2A 1267/4885OXER1 1382/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | KMO 3278/4885KMT2A 1129/4885OXER1 3506/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | KMO 313/4885KMT2A 1267/4885OXER1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.